Decera Clinical Education Oncology Podcast

In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of: Considerations with administration, including access challengesSequencing TherapiesFuture developments with BCMA-targeted therapiesPresenters:Suzanne Lentzsch, MD, PhDProfessor of MedicineDivision of Hematology/OncologyDirector, Multiple Myeloma and Amyloidosis ProgramColumbia University Medical Center New York, New YorkJoseph Mikhael, MD, MEd, FRCPC, FACPProfessorApplied Cancer Research and Drug Discovery Translational Genomics Research Institute Phoenix, ArizonaChief Medical OfficerInternational Myeloma Foundation HonorHealth Research Institute Scottsdale, ArizonaProvided by Clinical Care Options, LLC in partnership with Smart Patients.Content supported by educational grants from AbbVie; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; and Regeneron Pharmaceuticals, Inc.Link to full program: bit.ly/41YEOO6  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including:Overall approach to treatmentUse of JAK inhibitors for treating myelofibrosisTreating patients with low plateletsDefining JAK inhibitor failureUnmet needs in treatment and emerging therapeutic options, including momelotinib, luspatercept, ruxolitinib add-on therapy, and other phase III approachesPresenters: John Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Adult Leukemia ProgramLeader, Myeloproliferative Disorders Clinical Research ProgramDivision of Hematology/OncologyTisch Cancer InstituteNew York, New York Ruben A. Mesa, MD, FACPExecutive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer CenterEnterprise Senior Vice President, Atrium HealthPresident, Enterprise Cancer Service LineVice Dean for Cancer Programs, Wake Forest University School of MedicineProfessor of Medicine, Wake Forest University School of Medicine Winston-Salem, North Carolina Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of:  Data supporting the use of adjuvant PARP inhibition in early breast cancer and impact on BRCA testing and clinical practice The multidisciplinary role in ensuring that BRCA testing is completed for eligible patients Barriers to implementing BRCA testing and adjuvant olaparib in clinical practice and methods to overcome them Administration of adjuvant olaparib with other available adjuvant systemic therapiesTolerability of single-agent PARP inhibitors  Presenters:Banu Arun, MDProfessor, Breast Medical Oncology Director, Clinical Cancer Genetics University of Texas MD Anderson Cancer Center Houston, Texas  Allison Butts, PharmD, BCOPPharmacist Manager, Oncology Director, PGY2 Oncology Residency Program UK HealthCare Assistant Adjunct ProfessorUK College of Pharmacy Lexington, Kentucky Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNPNurse Practitioner Breast OncologyTexas Oncology Baylor Sammons Cancer Center Dallas, Texas  Content supported by educational grants from AstraZeneca and Merck Sharp & Dohme Corp. Link to full program:https://bit.ly/42VeUMM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including:Expression patterns and function of the claudin family of proteins in normal gastric tissuesBiologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncologyPrognostic implications of claudin 18.2 overexpression in gastric and gastroesophageal cancersLaboratory methodology involved in claudin 18.2 scoring as a potential predictive biomarker for patient selectionFuture directions for clinical development of agents targeting claudin 18.2, including monoclonal antibodies, bispecific antibodies, antibody‒drug conjugates, and CAR T-cell constructsPresenters:Samuel Klempner, MDAssociate ProfessorDepartment of MedicineDivision of Hematology-OncologyMass General Cancer CenterHarvard Medical SchoolBoston, MassachusettsGregory Botta, MD, PhDClinical Professor of MedicineDepartment of MedicineDivision of Hematology & OncologyUniversity of California San DiegoLa Jolla, CaliforniaContent for this program was supported by educational grants from Astellas and Bristol Myers Squibb.Link to the full program, including a CME-certified text module, downloadable slideset, and ClinicalThought (coming soon!):bit.ly/3lQxPrq Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include:When to use cytoreduction therapies and which therapies to use in low-risk patientsType 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reportsExperts’ thoughts on therapy options in higher-risk patientsPresenters:Prithviraj Bose, MDAssociate ProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of TexasMD Anderson Cancer CenterHouston, TexasAndrew Kuykendall, MDAssistant Professor Department of Oncologic SciencesUniversity of South FloridaAssistant MemberMalignant HematologyH. Lee Moffitt Cancer CenterTampa, Florida Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:bit.ly/3XF3cSF Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia.Topics discussed include:Practical considerations for management of allergy-like reactions and hypersensitivity to asparaginaseIndirect methods for measuring asparaginase activityStrategies to mitigate adverse events with asparaginase treatment, including hepatotoxicity, pancreatitis, and thrombosisConsiderations for use of asparaginase in special populations (eg, high BMI, older age)Presenters:Program DirectorDaniel J. DeAngelo, MD, PhDProfessor of MedicineDepartment of MedicineHarvard Medical SchoolChief of the Division of LeukemiaDepartment of Medical OncologyDivision of Hematologic MalignanciesDana‐Farber Cancer InstituteBoston, MassachusettsEmily Curran, MDAssistant ProfessorDivision of Hematology/OncologyUniversity of Cincinnati Cancer InstituteCincinnati, OhioKjeld Schmiegelow, MD, DMSciProfessorDepartment of Pediatric OncologyRighospitalet University HospitalCopenhagen, DenmarkContent based on an online CME program supported by an independent educational grant from Jazz Pharmaceuticals.Link to full program:http://bit.ly/3YXkLyj  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Steven M. Horwitz, MD; Pamela B. Allen, MD, MSc; and Kerry Savage, MD, MSc, answer questions from an audience of healthcare professionals on topics related to the management of T-cell lymphomas, including:Use of brentuximab vedotin in ≤1% CD-30‒expressing lymphomasStrategies with JAK inhibition and epigenetic agentsAllogeneic transplantation in cutaneous T-cell lymphomaPresenters: Steven M. Horwitz MDMember, Memorial Sloan Kettering Cancer Center Attending Physician, Memorial HospitalProfessor of Medicine, Weill Cornell Medical College New York, New YorkPamela B. Allen, MD, MScAssistant ProfessorDepartment of Hematology/OncologyEmory University, Winship Cancer InstituteThe Emory ClinicAtlanta, GeorgiaKerry Savage MD, MScProfessor of Medicine University of British ColumbiaMedical OncologistDivision of Medical OncologyBC Cancer Vancouver, British Columbia, CanadaContent for this program was supported by educational grants from Daiichi Sankyo; Kyowa Kirin, Inc.; and Seagen Inc. Link to the full program, including downloadable slides, expert commentary, and an on-demand webcast:bit.ly/3ItqEOd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including:  Practical use of the Molecular International Prognostic Scoring System  Mutational targets and other treatments in ongoing clinical trialsProphylaxis with venetoclax therapyBest practices for bone marrow transplant, including induction and salvage regimensTreatment options for hypoplastic myelodysplastic syndromesPresenters:Rami Komrokji, MDProfessorDepartment of Oncologic SciencesUniversity of South Florida  Vice ChairMalignant Hematology DepartmentMoffitt Cancer CenterTampa, FloridaMaría Díez Campelo, MD, PhDAssociate ProfessorDepartment of MedicineSchool of MedicineUniversity of SalamancaHematologistDepartment of HematologyUniversity Hospital of SalamancaSalamanca, SpainAmer Zeidan, MBBS, MHSAssociate Professor, Internal MedicineHematologyLeader, Leukemia and Myeloid Disease Aligned Research Team (DART)Director, Hematology Early Therapeutics ResearchYale Cancer Center and Smilow Cancer HospitalYale University School of MedicineNew Haven, ConnecticutLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:http://bit.ly/3YXgKK3   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC Current data and treatment strategies and the future of antibody–drug conjugates in the management of relapsed/refractory advanced TNBC Treatment implications of the presence of BRCA1/2 mutations and homologous recombination deficiency genes in advanced TNBCRole of PARP inhibitors in the treatment of TNBCPresenters: Mark Pegram, MDProfessor Medical OncologyStanford UniversityPalo Alto, CaliforniaSara Tolaney, MD, MPHAssociate Professor of MedicineDivision of Breast OncologyHarvard Medical SchoolChief, Division of Breast OncologyBreast Oncology ProgramDana-Farber Cancer InstituteBoston, MassachusettsContent based on an online CME/CE/CPE program supported by educational grants from Gilead Sciences, Inc.Link to full program:http://bit.ly/3iQzDz5 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include:Patient presentation and goals of frontline therapyConsiderations for second-line therapy in the setting of treatment intoleranceExperts’ thoughts on the potential of early intervention to alter disease progressionPresenters:Raajit Rampal, MD, PhDAssociate MemberAssociate Attending PhysicianLeukemia ServiceDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkBrady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, IllinoisContent for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:https://bit.ly/3X3x6jX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.